NJIT’s Kathleen McEnnis, assistant professor of chemical and materials engineering, is pioneering a new approach in cancer treatment through innovative drug-delivery nanoparticles. Her research focuses on treating aggressive types of breast cancer, using platinum-based nanoparticles that target cancer cells without damaging healthy tissue. This breakthrough could mark a significant step forward in minimizing the side effects of chemotherapy. McEnnis’s research team has found that these platinum nanoparticles, tested in vitro, effectively kill cancer cells while sparing healthy ones — an ideal outcome in targeted cancer therapy. Their work, funded by METAvivor, seeks to address a critical challenge: crossing the blood-brain barrier to treat cancer that has metastasized to the brain. To read the full story.